COMMUNIQUÉS West-GlobeNewswire

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma
27/02/2026
If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of [...]
Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF
27/02/2026
S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec [...]
BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance
27/02/2026
LOUISVILLE, Ky., Feb. 27, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex [...]
Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
27/02/2026
‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million ; GAAP Net Income of $35 million ; Diluted Income per Share of $0.11 [...]
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness
27/02/2026
Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 study demonstrating [...]
Communiqué de presse: L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif du CHMP comme traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil
27/02/2026
L’acoziborole Winthrop, développé par DNDi et Sanofi, reçoit l’avis positif du CHMP comme traitement à dose unique à trois comprimés pour la forme la plus fréquente de la maladie du sommeil La recommandation s’appuie [...]
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
27/02/2026
If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease [...]
Trading by management and close relations of management
27/02/2026
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the “Market Abuse Regulation”) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novonesis reports the [...]
ICPO and UroTeragLATAM signed a strategic agreement to accelerate Theranostics for urological cancer in Latin America
27/02/2026
The partnership strengthens education, innovation, and patient access by combining global expertise with regional leadership in precision oncology. February 27, 2026 – Wiesbaden, Germany and Miami, USA. The [...]
Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform
27/02/2026
Nature Medicine Accepts Manuscript Highlighting Clinical Results from the Company’s Glioblastoma Trial MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge ( [...]
Orion Group Financial Statement documents 2025 and Remuneration Report published
27/02/2026
ORION CORPORATION STOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT 27 FEBRUARY 2026 at 11.05 EET Orion Group Financial Statement documents 2025 and Remuneration Report published Orion Group's Financial Statement [...]
Santhera Announces Proposed Inclusion and Reimbursement of AGAMREE® (Vamorolone) within Spain’s National Health System for the Treatment of Duchenne Muscular Dystrophy
27/02/2026
Pratteln, Switzerland, February 27, 2026 – Santhera Pharmaceuticals (SIX: SANN) today announces that the Spanish Interministerial Commission on Prices of Medicines, has proposed to include AGAMREE® (vamorolone), in the [...]
Herz P1 Smart Band 2026: What It Tracks, How It Works, and What Consumers Should Know Before Buying
27/02/2026
A 2026 Informational Overview of the Herz P1 Smart Band's Subscription-Free Health Monitoring Features, Heart Rate and HRV Tracking, Sleep Quality Analysis, Blood Oxygen and SpO2 Sensors, Stress and Temperature [...]
QuickBurn BHB 2026: What Consumers Should Know About BHB Ketone Supplements Before Buying
27/02/2026
An informational overview of the QuickBurn BHB exogenous ketone supplement — ingredients, BHB salt research, potential side effects, ketosis claims, and what to verify before ordering. Largo, FL, Feb. 26, 2026 (GLOBE [...]
Inventiva to Participate in Four Upcoming March Investor Conferences
26/02/2026
Daix (France), New York (United States), February 26, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral [...]
The Kidney Foundation of Canada highlights need for Canadians to act on kidney health
26/02/2026
Take Action This Kidney Health Month and Ahead of World Kidney Day 2026 MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) -- As Kidney Health Month gets underway, The Kidney Foundation of Canada is calling on Canadians to take [...]
Inventiva participera à quatre conférences investisseurs en mars
26/02/2026
Daix (France), New York ( États-Unis ), le 26 février 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie [...]
Rapid Micro Biosystems to Present at TD Cowen 46th Annual Health Care Conference
26/02/2026
LEXINGTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
BGM Group Ltd. Receives NASDAQ Notice Related to Late Filing of Form 20-F
26/02/2026
CHENGDU, China, Feb. 26, 2026 (GLOBE NEWSWIRE) -- BGM Group Ltd. (NASDAQ: BGM) (the “Company” or “BGM”) announced on February 24, 2026, that it has received a notification (the “Notification”) from the Listing [...]

Pages